ReviewPharmaceuticals (Basel, Switzerland)2023
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Radiolabeled Angiopep-2 Peptide Vector as a Preclinical Platform for Blood-Brain Barrier Targeting: Synthesis, Radiolabeling, and Preliminary In Vivo Biodistribution in Mice.Journal of peptide science : an official publication of the European Peptide Society · 2026Article
- Design and development of a semi-automated solid target assembly for the indigenous production of medical radioisotopes in the PETrace-800 cyclotron.EJNMMI radiopharmacy and chemistry · 2026Article
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [ACS bio & med chem Au · 2026Article
- PET imaging of AAV9 and AAVBR1 trafficking in normal mice.Scientific reports · 2025Article
- Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.Nuclear medicine and molecular imaging · 2025Review
- Metal grafted graphene-based nanomaterials towards cancer theranostic efficacy.Exploration of targeted anti-tumor therapy · 2025Review
- Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Aspects and prospects of preclinical theranostic radiopharmaceutical development.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for imaging and radionuclide therapy, it is included in this review. In regard to radionuclide therapy, both beta-minus (β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.